Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells
References (24)
- et al.
Chem. Biol. Interactions
(1980) - et al.
Chem. Biol. Interactions
(1978) - et al.
Toxicol. Appl. Pharmacol
(1980) - et al.
Biochem. Pharmacol
(1983) - et al.
Arch. Biochem. Biophys
(1984) - et al.
Toxicol. Appl. Pharmacol
(1981) Arch. Biochem. Biophys
(1959)- et al.
Biochem. Pharmacol
(1974) - et al.
J. Clin. Hematol. and Oncol
(1977)
Biochem. J
(1980)
Biol. Tr. Ele. Res
(1983)
Cited by (63)
Metallothioneins
2021, Comprehensive Coordination Chemistry IIIEffect of chirality in platinum drugs
2015, Coordination Chemistry ReviewsCitation Excerpt :Thus, the transcriptional profiling approach can represent a unique tool for investigating differences between antitumor drugs belonging to the same family such as cisplatin and oxaliplatin or oxaliplatin and its S,S-enantiomer. Although scientists have initially focused on the characterization of platinum-DNA interaction [31], protein-bound platinum represents the most part of administered drug in the case of cisplatin, both in the extracellular medium (up to 98% of cisplatin interacts with albumin) [32] and into the cytoplasm [33], binding to S-donors being markedly favored [34]. Reactions occurring with cytosolic components are generally retained responsible for the broad spectrum of side effects [35], and contribute to resistance [36].
The role of metallothionein in oncogenesis and cancer prognosis
2009, Progress in Histochemistry and CytochemistryMetallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity
1998, Toxicology and Applied PharmacologyDirect reaction of H<inf>2</inf>O<inf>2</inf> with sulfhydryl groups in HL-60 cells: Zinc- metallothionein and other sites
1996, Archives of Biochemistry and Biophysics
Copyright © 1985 Published by Elsevier Inc.